Nitisinone Dipharma (Nitisinone)

Nitisinone selectively inhibits the enzyme 4‑hydroxyphenylpyruvate dioxygenase, which is essential for converting tyrosine into downstream metabolites. By blocking this enzyme, the drug stops the formation of harmful substances such as fumarylacetoacetate, reducing metabolic toxicity in patients with hereditary tyrosinemia type I.

The dosage of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory parameters. Healthcare professionals adjust the dose to achieve optimal metabolic control while minimizing adverse effects.

Safety data for nitisinone in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative approaches, such as liver transplantation, address end‑stage organ damage but do not correct the underlying enzymatic deficiency. Nitisinone therefore offers a less invasive, long‑term management option.

Nitisinone Dipharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually as a tablet or capsule, with water. It can be taken with or without food, but consistent administration with regard to meals helps maintain stable plasma concentrations. Patients should follow the prescribing clinician’s instructions for timing and dosing.

Serious risks include liver failure, severe hypoglycemia, neutropenia, peripheral neuropathy, and rare anaphylactic reactions. Patients should be monitored regularly for liver enzymes, blood glucose, complete blood counts, and any neurological symptoms. Prompt medical attention is required if serious adverse events are suspected.

Nitisinone is contraindicated in individuals with known hypersensitivity to nitisinone or any of its excipients. Caution is advised for patients with severe hepatic impairment, uncontrolled metabolic disorders, or those taking interacting medications that may exacerbate toxicity. The drug should only be used under specialist supervision.